Abbott Laboratories (FRA:ABL) Net Income From Continuing Operations : €5,203 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Abbott Laboratories Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Abbott Laboratories's net income from continuing operations for the three months ended in Mar. 2024 was €1,127 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €5,203 Mil.

Abbott Laboratories Net Income From Continuing Operations Historical Data

The historical data trend for Abbott Laboratories's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Net Income From Continuing Operations Chart

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

3,318.30

3,694.89

6,257.84

6,544.75

5,247.99

Abbott Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,231.01	1,269.13	1,345.53	1,461.70	1,127.00

Abbott Laboratories Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5,203 Mil.

Abbott Laboratories (FRA:ABL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (FRA:ABL) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ABT:USA ABT:Mexico 0Q15:UK ABL:Germany ABT:Chile ABT:Switzerland ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.